Figure 6.

Protein regulation in serum in inflammatory bowel disease (IBD) after treatments. IBD groups were classified according with their pharmacologic therapy as follows: controls, 5-aminosalicylic acid (5-ASA), 5-ASA + Azathioprine, and 5-ASA + Azathiopirine + Adalimumab. The growth factors (blue), proinflammatory cytokines (green), chemokines (orange), and antiinflammatory cytokines (yellow) are displayed in the figure according with their upregulation (arrows up) or downregulation (arrows down) and the pharmacologic therapy group. The up- or downregulation was obtained from the protein serum levels comparisons between IBD cases and controls. Compared with controls, the combined therapy with 5-ASA + Azathiopirine + Adalimumab showed a remarkable effect on the circulating cytokine modulation.